title: Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation.
abstract: Prostaglandin E1 (PGE1) was used to prevent veno-occlusive disease (VOD) of the liver after allogeneic bone marrow transplantation (BMT) for leukaemia. It was given in continuous i.v. infusion from day--8 to day 30 after BMT at a dose of 0.3 micrograms/kg/h. The patients were studied according to the risk factors for VOD: diagnosis, intensification of the conditioning and previous liver abnormalities. The diagnosis of VOD was made on at least two of the following factors: weight gain, hepatomegaly, jaundice, ascitis, pain of the right upper quadrant, increased platelet consumption. 109 patients were studied, 50 were treated by PGE1 and 59 did not receive it. The actuarial incidence of VOD was 12.2% in the PGE1 group and 25.5% in the non PGE1 group (P = 0.05). In acute leukaemia, the incidence was 39.1% in the non-treated group and 12.8% in the PGE1 treated group (P = 0.02). Patients with previous hepatitis had an incidence of 62.5% in the non treated group and 15.5% in the treated group (P = 0.05). A positive cytomegalovirus (CMV) serology seemed to increase the risk of VOD: the incidence of VOD was 31.4% in non-treated patients and 22% in PGE1 treated patients. The multivariate analysis of the risk factors for VOD shows that unfavourable factors were: recipient positive CMV serology (P = 0.06), hepatic disease prior to transplant (P = 0.02) and the absence of PGE1 treatment (P = 0.02). This study suggests that prophylactic PGE1 treatment may decrease the incidence of VOD in patients treated for leukaemia by allogeneic bone marrow transplantation.
authors.affiliation: Bone Marrow Transplant Unit, Hopital Saint-Louis, Paris, France.
authors.forename: E
authors.initials: E
authors.lastname: Gluckman
authors.forename: I
authors.initials: I
authors.lastname: Jolivet
authors.forename: M L
authors.initials: ML
authors.lastname: Scrobohaci
authors.forename: A
authors.initials: A
authors.lastname: Devergie
authors.forename: R
authors.initials: R
authors.lastname: Traineau
authors.forename: H
authors.initials: H
authors.lastname: Bourdeau-Esperou
authors.forename: P
authors.initials: P
authors.lastname: Lehn
authors.forename: P
authors.initials: P
authors.lastname: Faure
authors.forename: L
authors.initials: L
authors.lastname: Drouet
mesh_terms: D000328:Adult; D000527:Alprostadil / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D003586:Cytomegalovirus Infections / Q000150:complications; D006504:Hepatic Veno-Occlusive Disease / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007938:Leukemia / Q000601:surgery*; D008107:Liver Diseases / Q000150:complications; D012307:Risk Factors
chemical_list: D000527:Alprostadil